Literature DB >> 18573893

Comparison of the susceptibilities of C57BL/6 and A/J mouse strains to Streptococcus suis serotype 2 infection.

María de la Cruz Domínguez-Punaro1, Mariela Segura, Danuta Radzioch, Serge Rivest, Marcelo Gottschalk.   

Abstract

Streptococcus suis is an important swine and human pathogen. Assessment of susceptibility to S. suis using animal models has been limited to monitoring mortality rates. We recently developed a hematogenous model of S. suis infection in adult CD1 outbred mice to study the in vivo development of an early septic shock-like syndrome that leads to death and a late phase that clearly induces central nervous system damage, including meningitis. In the present study, we compared the severities of septic shock-like syndrome caused by S. suis between adult C57BL/6J (B6) and A/J inbred mice. Clinical parameters, proinflammatory mediators, and bacterial clearance were measured to dissect potential immune factors associated with genetic susceptibility to S. suis infection. Results showed that A/J mice were significantly more susceptible than B6 mice to S. suis infection, especially during the acute septic phase of infection (100% of A/J and 16% of B6 mice died before 24 h postinfection). The greater susceptibility of A/J mice was associated with an exaggerated inflammatory response, as indicated by their higher production of tumor necrosis factor alpha, interleukin-12p40/p70 (IL-12p40/p70), gamma interferon, and IL-1beta, but not with different bacterial loads in the blood. In addition, IL-10 was shown to be responsible, at least in part, for the higher survival in B6 mice. Our findings demonstrate that A/J mice are very susceptible to S. suis infection and provide evidence that the balance between pro- and anti-inflammatory mediators is crucial for host survival during the septic phase.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18573893      PMCID: PMC2519407          DOI: 10.1128/IAI.00350-08

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  49 in total

1.  Interleukin-10 determines viral clearance or persistence in vivo.

Authors:  David G Brooks; Matthew J Trifilo; Kurt H Edelmann; Luc Teyton; Dorian B McGavern; Michael B A Oldstone
Journal:  Nat Med       Date:  2006-10-15       Impact factor: 53.440

2.  Combination immunotherapy with soluble tumor necrosis factor receptors plus interleukin 1 receptor antagonist decreases sepsis mortality.

Authors:  D G Remick; D R Call; S J Ebong; D E Newcomb; P Nybom; J A Nemzek; G E Bolgos
Journal:  Crit Care Med       Date:  2001-03       Impact factor: 7.598

Review 3.  The pathogenesis of the meningitis caused by Streptococcus suis: the unresolved questions.

Authors:  M Gottschalk; M Segura
Journal:  Vet Microbiol       Date:  2000-10-01       Impact factor: 3.293

Review 4.  Genetic regulation of host responses to group A streptococcus in mice.

Authors:  Eva Medina; Andreas Lengeling
Journal:  Brief Funct Genomic Proteomic       Date:  2005-11

5.  TLR2-dependent recognition of Streptococcus suis is modulated by the presence of capsular polysaccharide which modifies macrophage responsiveness.

Authors:  Richard Graveline; Mariela Segura; Danuta Radzioch; Marcelo Gottschalk
Journal:  Int Immunol       Date:  2007-02-16       Impact factor: 4.823

6.  Proinflammatory cytokine and chemokine modulation by Streptococcus suis in a whole-blood culture system.

Authors:  Mariela Segura; Ghyslaine Vanier; Dina Al-Numani; Sonia Lacouture; Martin Olivier; Marcelo Gottschalk
Journal:  FEMS Immunol Med Microbiol       Date:  2006-06

7.  Phagocytosis and killing of Streptococcus suis by porcine neutrophils.

Authors:  Geneviève Chabot-Roy; Philip Willson; Mariela Segura; Sonia Lacouture; Marcelo Gottschalk
Journal:  Microb Pathog       Date:  2006-05-22       Impact factor: 3.738

8.  Streptococcus suis serotype 2, an important swine and human pathogen, induces strong systemic and cerebral inflammatory responses in a mouse model of infection.

Authors:  María C Domínguez-Punaro; Mariela Segura; Marie-Michèle Plante; Sonia Lacouture; Serge Rivest; Marcelo Gottschalk
Journal:  J Immunol       Date:  2007-08-01       Impact factor: 5.422

Review 9.  Streptococcus suis infections in humans: the Chinese experience and the situation in North America.

Authors:  Marcelo Gottschalk; Mariela Segura; Jiangu Xu
Journal:  Anim Health Res Rev       Date:  2007-06       Impact factor: 2.615

10.  Human Streptococcus suis outbreak, Sichuan, China.

Authors:  Hongjie Yu; Huaiqi Jing; Zhihai Chen; Han Zheng; Xiaoping Zhu; Hua Wang; Shiwen Wang; Lunguang Liu; Rongqiang Zu; Longze Luo; Nijuan Xiang; Honglu Liu; Xuecheng Liu; Yuelong Shu; Shui Shan Lee; Shuk Kwan Chuang; Yu Wang; Jianguo Xu; Weizhong Yang
Journal:  Emerg Infect Dis       Date:  2006-06       Impact factor: 6.883

View more
  42 in total

1.  Role of capsule and suilysin in mucosal infection of complement-deficient mice with Streptococcus suis.

Authors:  Maren Seitz; Andreas Beineke; Alena Singpiel; Jörg Willenborg; Pavel Dutow; Ralph Goethe; Peter Valentin-Weigand; Andreas Klos; Christoph G Baums
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

2.  Role of fibronectin-binding proteins A and B in in vitro cellular infections and in vivo septic infections by Staphylococcus aureus.

Authors:  Hitomi Shinji; Yukio Yosizawa; Akiko Tajima; Tadayuki Iwase; Shinya Sugimoto; Keiko Seki; Yoshimitsu Mizunoe
Journal:  Infect Immun       Date:  2011-03-21       Impact factor: 3.441

3.  Interaction of factor H-binding protein of Streptococcus suis with globotriaosylceramide promotes the development of meningitis.

Authors:  Decong Kong; Zhe Chen; Junping Wang; Qingyu Lv; Hua Jiang; Yuling Zheng; Maokai Xu; Xuyu Zhou; Huaijie Hao; Yongqiang Jiang
Journal:  Virulence       Date:  2017-04-12       Impact factor: 5.882

4.  In vitro characterization of the microglial inflammatory response to Streptococcus suis, an important emerging zoonotic agent of meningitis.

Authors:  María de la Cruz Domínguez-Punaro; Mariela Segura; Irazú Contreras; Claude Lachance; Mathieu Houde; Marie-Pier Lecours; Martin Olivier; Marcelo Gottschalk
Journal:  Infect Immun       Date:  2010-09-27       Impact factor: 3.441

5.  Severe cochlear inflammation and vestibular syndrome in an experimental model of Streptococcus suis infection in mice.

Authors:  M C Domínguez-Punaro; U Koedel; T Hoegen; C Demel; M Klein; M Gottschalk
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2012-03-01       Impact factor: 3.267

6.  Amentoflavone Ameliorates Streptococcus suis-Induced Infection In Vitro and In Vivo.

Authors:  Xue Shen; Xiaodi Niu; Gen Li; Xuming Deng; Jianfeng Wang
Journal:  Appl Environ Microbiol       Date:  2018-11-30       Impact factor: 4.792

7.  Streptococcus suis Serotype 2 Infection Causes Host Immunomodulation through Induction of Thymic Atrophy.

Authors:  Ganwu Li; Gang Wang; Shujie Wang; Chuang Lyu; Guixin Duan; Fandan Meng; Yongbo Yang; Ying Yu; Xijun He; Zhenzhong Wang; Marcelo Gottschalk; Xuehui Cai
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

8.  Catabolite control protein A of Streptococcus suis type 2 contributes to sugar metabolism and virulence.

Authors:  Yulong Tang; Wei Wu; Xiaoyan Zhang; Zhongyan Lu; Jianshun Chen; Weihuan Fang
Journal:  J Microbiol       Date:  2012-12-30       Impact factor: 3.422

9.  Cellular mosaicism for X-linked polymorphisms and IRAK1 expression presents a distinct phenotype and improves survival following sepsis.

Authors:  Rachna Chandra; Stephanie Federici; Zoltán H Németh; Balázs Csóka; James A Thomas; Robert Donnelly; Zoltán Spolarics
Journal:  J Leukoc Biol       Date:  2013-11-05       Impact factor: 4.962

10.  Mutations in the gene encoding the ancillary pilin subunit of the Streptococcus suis srtF cluster result in pili formed by the major subunit only.

Authors:  Nahuel Fittipaldi; Daisuke Takamatsu; María de la Cruz Domínguez-Punaro; Marie-Pier Lecours; Diane Montpetit; Makoto Osaki; Tsutomu Sekizaki; Marcelo Gottschalk
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.